Codice QR

Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP

Current human papillomavirus (HPV) vaccines provide substantial protection against the most common HPV types responsible for oral and anogenital cancers, but many circulating cancer-causing types remain for which vaccine coverage is lacking. In addition, all current HPV vaccines rely on aluminum sal...

Descrizione completa

Salvato in:
Autori principali: Sarah M. Valencia, Athina Zacharia, Alexander Marin, Rebecca L. Matthews, Chia-Kuei Wu, Breana Myers, Chelsea Sanders, Simone Difilippantonio, Reinhard Kirnbauer, Richard B. Roden, Ligia A. Pinto, Robert H. Shoemaker, Alexander K. Andrianov, Jason D. Marshall
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis Group 2021-08-01
Serie:Human Vaccines & Immunotherapeutics
Soggetti:
human papillomavirus
hpv
prophylactic vaccine
pcep
polyphosphazenes
adjuvants
hpv-l2
neutralizing antibody
Accesso online:http://dx.doi.org/10.1080/21645515.2021.1875763
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi